BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 23107876)

  • 1. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.
    Wulff H; Köhler R
    J Cardiovasc Pharmacol; 2013 Feb; 61(2):102-12. PubMed ID: 23107876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.
    Brown BM; Shim H; Christophersen P; Wulff H
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():219-240. PubMed ID: 31337271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
    Wulff H; Kolski-Andreaco A; Sankaranarayanan A; Sabatier JM; Shakkottai V
    Curr Med Chem; 2007; 14(13):1437-57. PubMed ID: 17584055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.
    Oliván-Viguera A; Valero MS; Murillo MD; Wulff H; García-Otín AL; Arbonés-Mainar JM; Köhler R
    PLoS One; 2013; 8(3):e58614. PubMed ID: 23516517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
    Sankaranarayanan A; Raman G; Busch C; Schultz T; Zimin PI; Hoyer J; Köhler R; Wulff H
    Mol Pharmacol; 2009 Feb; 75(2):281-95. PubMed ID: 18955585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial Small- and Intermediate-Conductance K Channels and Endothelium-Dependent Hyperpolarization as Drug Targets in Cardiovascular Disease.
    Köhler R; Oliván-Viguera A; Wulff H
    Adv Pharmacol; 2016; 77():65-104. PubMed ID: 27451095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery.
    Grgic I; Kaistha BP; Hoyer J; Köhler R
    Br J Pharmacol; 2009 Jun; 157(4):509-26. PubMed ID: 19302590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial K
    Li JJ; Zhao XY; Wang Y; Xu R; Di XH; Zhang Y; Yang H; Han MZ; Bai RY; Xie L; Pang ZD; Zhang X; Zhang J; Du XJ; Deng XL; Zhang Y; Xie W
    Arterioscler Thromb Vasc Biol; 2023 May; 43(5):726-738. PubMed ID: 36951065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary hypertension in wild type mice and animals with genetic deficit in KCa2.3 and KCa3.1 channels.
    Wandall-Frostholm C; Skaarup LM; Sadda V; Nielsen G; Hedegaard ER; Mogensen S; Köhler R; Simonsen U
    PLoS One; 2014; 9(5):e97687. PubMed ID: 24858807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.
    Hasenau AL; Nielsen G; Morisseau C; Hammock BD; Wulff H; Köhler R
    Acta Physiol (Oxf); 2011 Sep; 203(1):117-26. PubMed ID: 21362152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs.
    Damkjaer M; Nielsen G; Bodendiek S; Staehr M; Gramsbergen JB; de Wit C; Jensen BL; Simonsen U; Bie P; Wulff H; Köhler R
    Br J Pharmacol; 2012 Jan; 165(1):223-34. PubMed ID: 21699504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).
    Christophersen P; Wulff H
    Channels (Austin); 2015; 9(6):336-43. PubMed ID: 26217968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prominent role of KCa3.1 in endothelium-derived hyperpolarizing factor-type dilations and conducted responses in the microcirculation in vivo.
    Wölfle SE; Schmidt VJ; Hoyer J; Köhler R; de Wit C
    Cardiovasc Res; 2009 Jun; 82(3):476-83. PubMed ID: 19218287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of
    Kloza M; Baranowska-Kuczko M; Toczek M; Kusaczuk M; Sadowska O; Kasacka I; Kozłowska H
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laminar shear stress upregulates endothelial Ca²⁺-activated K⁺ channels KCa2.3 and KCa3.1 via a Ca²⁺/calmodulin-dependent protein kinase kinase/Akt/p300 cascade.
    Takai J; Santu A; Zheng H; Koh SD; Ohta M; Filimban LM; Lemaître V; Teraoka R; Jo H; Miura H
    Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H484-93. PubMed ID: 23792675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Channelopathy of small- and intermediate-conductance Ca
    Nam YW; Downey M; Rahman MA; Cui M; Zhang M
    Acta Pharmacol Sin; 2023 Feb; 44(2):259-267. PubMed ID: 35715699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end products impair K(Ca)3.1- and K(Ca)2.3-mediated vasodilatation via oxidative stress in rat mesenteric arteries.
    Zhao LM; Wang Y; Ma XZ; Wang NP; Deng XL
    Pflugers Arch; 2014 Feb; 466(2):307-17. PubMed ID: 23873353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preserved regulation of renal perfusion pressure by small and intermediate conductance KCa channels in hypertensive mice with or without renal failure.
    Waeckel L; Bertin F; Clavreul N; Damery T; Köhler R; Paysant J; Sansilvestri-Morel P; Simonet S; Vayssettes-Courchay C; Wulff H; Verbeuren TJ; Félétou M
    Pflugers Arch; 2015 Apr; 467(4):817-31. PubMed ID: 24903240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of DOCA-salt hypertension and chronic administration of the FAAH inhibitor URB597 on K
    Kloza M; Baranowska-Kuczko M; Malinowska B; Karpińska O; Harasim-Symbor E; Kasacka I; Kozłowska H
    Vascul Pharmacol; 2017 Dec; 99():65-73. PubMed ID: 29038048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory and anti-fibrotic effects of modafinil in nonalcoholic liver disease.
    Choi S; Kim JA; Li H; Jo SE; Lee H; Kim TH; Kim M; Kim SJ; Suh SH
    Biomed Pharmacother; 2021 Dec; 144():112372. PubMed ID: 34794237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.